A phase III study of Amantadine (ADS-5102) for the treatment of multiple sclerosis (MS).

Trial Profile

A phase III study of Amantadine (ADS-5102) for the treatment of multiple sclerosis (MS).

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2016

At a glance

  • Drugs Amantadine (Primary)
  • Indications Movement disorders; Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 15 Jan 2016 New trial record
    • 12 Jan 2016 According to a media release of Adamas pharmaceuticals, this trial will initiate in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top